Alphabet's double-digit rally has lent credibility to our prior strong buy rating, with it apparent that the ongoing AI boom has boosted its cloud/advertising performance. With expanding cloud market share at the expense of its competitors and richer profit margins, this remains early innings to its AI growth story, as Gemini competes with OpenAI's GPT-5. The AI benefit has also been observed in GOOG's improved advertising performance, as similarly reported by META, with the segment remaining the former's top/bottom-line growth driver.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Invivyd's monoclonal antibody (mAb) VYD2311 is a prophylactic for COVID has greater efficacy and less side effects than COVID vaccines. The current administration's clear goal of minimizing the prevalence of COVID vaccines should only hasten the realization of VYD2311 as a superior treatment option for those at risk. The FDA recently agreed to a rather favorable regulatory pathway for VYD2311, in start contrast to the punitive regulatory changes it made to COVID vaccine development in May.

CVX secures a 10-year deal to supply 650,000 metric tons of LNG annually to China, boosting its global clean energy reach.

MainStreet Bank (MNSB) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, 8x8 (EGHT) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

StoneX Group (SNEX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Century (CENX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Brink's (BCO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Guess (GES) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Euroseas (ESEA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

inTest (INTT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

InfuSystems Holdings (INFU) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, KT Corp. (KT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Bridgewater (BWB) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Cushman & Wakefield (CWK) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Brown-Forman published its results for the first quarter of fiscal 2026 yesterday, which were received negatively by the market. In this article, I share my take on BF.A/BF.B's Q1 FY2026 results, focusing on profitability, the problematic inventory situation, and of course leverage. I also explain my strategy for investing in BF.A going forward, a stock that I believe could remain "dead money" for the foreseeable future.

The company maintains an ability to adapt to market trends, which is reflected, for example, in the fact that 70% of its routes are located west of the Suez Canal. The company's debt decreased from nearly $300 million at the end of 2022 to $32 million today. If we look at the value that the company reported in 1H2025 for adjusted EBITDA, we see that the value amounts to $51.65 million, which implies an EV/EBITDA of 2.18x.